Operator

Ladies and gentlemen, welcome to the Immunovia Q1 interim report 2026 conference call. I'm Lorenzo, the Chorus Call operator. [Operator Instructions] The conference is being recorded. [Operator Instructions] The conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to Peter Hongaard. Please go ahead.

Peter Andersen

Thank you. Yes. My name is as introduced, Peter Hongaard. I'm the Chairman of the Board. And if you could forward to the first slide, please. It's a pleasure for me to participate in this webcast today, which we're going to do a little bit different. The difference is that we're going to provide you with somewhat more forward-looking statements and give you an idea about the interesting and exciting milestones which Immunovia is going to meet over the next year or so towards being a full-fledged commercial company.

And in order to incentivize this, we have also put an incentivizing scheme in place, both for management, but also for the Board itself. And I'll come back to that a little later in the presentation.

But first, I handing over to Jeff to explain more details about the company today and the plans going forward. Jeff, please?

Jeff Borcherding
Global Chief Executive Officer & President

Thanks very much for the introduction, Peter, and great to have you on the call today.

I'd like to start by talking about our plan for 2026 and really what extends beyond that as well. As we do that, I'll cover key results from the first quarter as we think